California Proposition 38 would authorize $8.4 billion in general obligation bonds for immunology and immunotherapy research, allocating roughly half to a designated University of California-affiliated institute and the rest through competitive grants focused on cancer, heart disease, and Alzheimer’s. Trader consensus remains closely balanced near 52 percent for passage because support for expanded state-backed medical research competes with concerns over annual General Fund repayment costs estimated at $500 million for 25 years, the measure’s narrow eligibility criteria that appear to direct the largest share to one specific nonprofit, and questions about long-term fiscal returns. Recent July reporting on the initiative’s structure and backers has sustained scrutiny, while upcoming endorsements, campaign spending disclosures, and any new fiscal analyses before the November 2026 vote could shift probabilities in either direction.